Group 1 - The stock price of Anglikon Pharmaceuticals dropped by 5.06% to 43.49 CNY per share, with a trading volume of 363 million CNY and a turnover rate of 4.37%, resulting in a total market capitalization of 8.773 billion CNY [1] - Anglikon Pharmaceuticals, established on December 30, 2001, and listed on October 23, 2018, is primarily engaged in the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikon Pharmaceuticals includes formulations at 43.46%, raw materials at 39.82%, specialty intermediates at 12.44%, other products at 3.72%, and pharmaceutical excipients at 0.56% [1] Group 2 - In the second quarter, Invesco Great Wall Fund held 48,000 shares of Anglikon, representing 4.95% of the fund's net value, making it the eighth largest holding [2] - The Invesco Great Wall Medical Industry Stock A fund, established on January 24, 2025, has a latest scale of 15.9413 million CNY and has achieved a return of 72.54% since inception [2] - The fund manager, Qiao Haiying, has a tenure of 10 years and 361 days, with total assets under management of 327 million CNY, achieving a best return of 147.43% and a worst return of -11.7% during the tenure [2]

Company Overview - Zhejiang Angli Kang Pharmaceutical Co., Ltd. is located at 1000 North Shengzhou Avenue, Shengzhou City, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018 [1] - The company's main business involves the research, production, and sales of chemical raw materials and formulations [1] Revenue Composition - The revenue composition of the company is as follows: formulations account for 43.46%, raw materials 39.82%, specialty intermediates 12.44%, others 3.72%, and pharmaceutical excipients 0.56% [1] Stock Performance - On September 4, the stock price of Angli Kang fell by 5.06%, closing at 43.49 CNY per share, with a trading volume of 363 million CNY and a turnover rate of 4.37%, resulting in a total market capitalization of 8.773 billion CNY [1] Fund Holdings - According to data, one fund under Lobo Mai holds a significant position in Angli Kang, specifically the Lobo Mai China Healthcare Equity Fund A (020142), which held 35,500 shares, representing 4.5% of the fund's net value, making it the eighth largest holding [2] - The fund has a current size of 14.5216 million CNY and has achieved a year-to-date return of 46.7%, ranking 327 out of 4222 in its category [2] Fund Manager Performance - The fund manager of Lobo Mai China Healthcare Equity Fund A is Li Tao, who has been in the position for 1 year and 254 days, with total assets under management of 29.2458 million CNY [3] - During Li Tao's tenure, the best fund return was 17.87%, while the worst return was 16.66% [3]

Company Overview - Angli康 is a pharmaceutical company based in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company specializes in the research, production, and sales of chemical raw materials and formulations [1]. - The main business revenue composition includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1]. Stock Performance - As of September 1, Angli康's stock price increased by 2.00% to 50.41 CNY per share, with a trading volume of 215 million CNY and a turnover rate of 2.34%, resulting in a total market capitalization of 10.169 billion CNY [1]. - Year-to-date, Angli康's stock price has risen by 286.05%, but it has seen a decline of 9.37% over the last five trading days and 22.09% over the last 20 days. In the last 60 days, the stock price increased by 134.92% [1]. Financial Performance - For the first half of 2025, Angli康 reported a revenue of 724 million CNY, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.925 million CNY, down 3.19% year-on-year [2]. - Since its A-share listing, Angli康 has distributed a total of 341 million CNY in dividends, with 108 million CNY distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, Angli康 had 18,500 shareholders, an increase of 50.49% from the previous period. The average number of circulating shares per person decreased by 33.55% to 10,037 shares [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, holding 6.4373 million shares, and Guangfa Technology Innovation Mixed A, holding 6.1606 million shares [3].

Company Overview - Zhejiang Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, and is a modern pharmaceutical enterprise integrating the research and production of pharmaceutical intermediates, active pharmaceutical ingredients, and formulations [1] - The company covers multiple therapeutic areas including anti-infection, cardiovascular, and anesthesia pain relief, and has established a complete pharmaceutical industry chain [1] - Anglikang is the largest global producer of α-keto acid active pharmaceutical ingredients and has core products included in national centralized procurement, consistently ranking among the top 200 in China's pharmaceutical industry in recent years [1] Stock Performance - On August 25, Anglikang's stock reached a 10.01% limit up, trading at 55.62 yuan per share, with a transaction volume of 537 million yuan and a turnover rate of 5.38%, resulting in a total market capitalization of 11.22 billion yuan [1] Financial Performance - For the period from January to March 2025, Anglikang reported an operating revenue of 346 million yuan, a year-on-year decrease of 15.31% [1] - The net profit attributable to shareholders was 15.91 million yuan, reflecting a year-on-year decline of 43.63% [1] - As of March 31, the number of shareholders was 12,300, with an average of 15,100 circulating shares per shareholder [1]

Core Viewpoint - The company has approved a share repurchase plan to buy back a portion of its publicly issued shares using its own funds and a special loan, with a total repurchase amount between RMB 50 million and RMB 70 million, and a maximum price of RMB 21.07 per share [1] Group 1: Share Repurchase Plan - The company plans to use its own funds and a special loan to repurchase shares, with a total amount not less than RMB 50 million and not exceeding RMB 70 million [1] - The repurchase price will not exceed RMB 21.07 per share, and the actual number of shares repurchased will depend on the execution [1] - The implementation period for the repurchase is set for up to 12 months from the board's approval date [1] Group 2: Progress of Repurchase - As of July 31, 2025, the company has repurchased a total of 3,599,700 shares, accounting for approximately 1.78% of the total share capital [2] - The highest transaction price during the repurchase was RMB 17.00 per share, while the lowest was RMB 12.17 per share, with a total transaction amount of RMB 50,001,275.28 (excluding transaction fees) [2] Group 3: Compliance and Regulations - The company has adhered to the regulations set forth by the Shenzhen Stock Exchange regarding share repurchase, including not repurchasing during significant events that could impact share prices [3] - The repurchase transactions comply with the requirements that the entrusted price must not exceed the daily trading limit and must not occur during specific trading periods [3] - The company will continue to implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by law [3]